 |
|
|
| |
Utilizing Phase 3 Clinical Trial Data to Assess Adverse Event (AE) Frequency of a Potentially Interacting Medication (PIM) Amlodipine with Elvitegravir/Cobicistat (EVG/COBI)
|
| |
| |
Reported by Jules Levin
HIV Glasgow, 23-26 October 2016, Glasgow, UK
D Podzamczer1, K Tashima2, E Daar3, J McGowan4, T Campbell5, J Slim6, M Thompson7,
S Guo8, P Borg9, M Das8, R Haubrich8, I McNicholl8, S McCallister8
1Hospital Universitari de Bellvitge, Barcelona, Spain; 2The Miriam Hospital, Providence, RI, USA; 3Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA;
4North Shore University Hospital, Manhasset, NY, USA; 5University of Colorado, Denver, CO, USA; 6Saint Michael's Medical Center, Newark, NJ, USA;
7AIDS Research Consortium of Atlanta, Atlanta, GA, USA; 8Gilead Sciences, Foster City, CA, USA; 9Gilead Sciences, Stockley Park, UK
|
| |
|
|
|
|
|
